Bifidobacteria-derived exopolysaccharide promotes anti-tumor immunity

Area of Science:

• Immunology
• Microbiology
• Cancer Research

Background:

• Understanding mechanisms of bacterial influence on cancer immunotherapies is crucial.
• Microbial therapeutics face safety and regulatory challenges, necessitating alternative approaches.
• Bacterial-derived molecules offer promising, non-replicative alternatives for cancer treatment.

Purpose of the Study:

• To identify bacterial-derived molecules that promote anti-tumor immunity.
• To elucidate the mechanisms by which these molecules enhance anti-tumor responses.
• To evaluate the potential of bacterial exopolysaccharides (EPSs) as adjuvant cancer immunotherapy.

Main Methods:

• Identification and characterization of exopolysaccharides (EPSs) from Bifidobacterium species.
• Assessment of EPS effects on T cell immunity and tumor cell killing in murine colon cancer models.
• Investigation of EPS sensing pathways in dendritic cells (DCs) using Toll-like receptor 2 (TLR2) and MyD88.
• Measurement of cytokine production (IL-12, TNF-α) in response to EPS stimulation.
• Evaluation of EPS-induced immune cell-mediated tumor cell death in patient-derived colon cancer organoids.

Main Results:

• Exopolysaccharides (EPSs) from Bifidobacterium pseudolongum and Bifidobacterium pseudocatenulatum significantly improved Th1 T cell immunity.
• EPSs induced interleukin (IL)-12 and tumor necrosis factor (TNF)-α production in dendritic cells via a TLR2-MyD88-dependent pathway.
• IL-12 and TNF-α were essential for T cell-mediated killing of tumor cells in vivo.
• EPSs promoted immune cell-mediated cell death in patient-derived colon cancer organoids.

Conclusions:

• Microbe-derived exopolysaccharides (EPSs) possess potent adjuvant immunotherapy properties.
• EPSs stimulate anti-tumor immunity through dendritic cell activation and subsequent T cell responses.
• EPSs represent a promising alternative for enhancing cancer immunotherapy efficacy.